Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
Numinus Wellness Inc. (NUMIF) is a leader in developing evidence-based psychedelic-assisted therapies for mental health conditions. This dedicated news hub provides investors and stakeholders with centralized access to official updates and strategic developments.
Track critical announcements including clinical trial milestones, regulatory progress, partnership agreements, and financial performance reports. Our curated collection ensures efficient monitoring of Numinus' advancements in depression, anxiety, and trauma treatments through integrated clinic networks and research initiatives.
Key updates cover three strategic pillars: clinical research breakthroughs validating therapeutic protocols, clinic network expansions enhancing patient access, and practitioner training programs ensuring treatment quality. Receive timely alerts on patent filings, research collaborations, and operational optimizations.
Bookmark this page for streamlined tracking of Numinus' progress in transforming mental healthcare through FDA-compliant research and reimbursable treatment models. Visit regularly to stay informed about this innovative leader in psychedelic-assisted therapy development.
Numinus Wellness (OTCQB:NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q2 2025 financial results. The company achieved total revenue of C$1.51 million, representing an 83.8% increase from Q2 2024. Despite revenue growth, gross profit margin declined to 33.4% from 55.6% year-over-year.
The company reported a comprehensive loss of C$7.71 million, wider than the previous year's loss of C$5.96 million. Operating expenses increased by 86.31% to C$9.89 million. As of February 28, 2025, Numinus maintained cash and cash equivalents of C$705,631.
Numinus Wellness (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q1 2025 financial results. The company achieved significant revenue growth of 68.3%, reaching $2.01 million compared to $1.20 million in Q1 2024.
The company demonstrated improved operational efficiency with a gross profit margin increase to 49.3% from 38.6% year-over-year. Operating expenses decreased substantially by 51.1% to $2.07 million. The net loss narrowed to $1.29 million from $4.35 million in the prior year. As of November 30, 2024, Numinus maintained a cash position of $2.0 million.
Numinus Wellness Inc. (OTCQB:NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q4 2024 financial results. The company achieved revenue of $1.2 million, marking a 16.4% increase from Q3 2024, with a gross profit of $0.3 million.
Key developments include the sale of its wellness clinic network to Stella for US$3.53 million, leadership changes with Michael Tan appointed as CEO, and the approval of its Psychedelic-Assisted Therapy Training Program in Colorado. Cedar Clinical Research (CCR) managed 18 clinical trials and was selected as one of 15 U.S. research sites for Cybin's Phase 3 trial of CYB003 for Major Depressive Disorder.
The company ended Q4 with $2.0 million in cash and has successfully transitioned to a leaner operation, focusing on growth through its clinical research and practitioner training segments.
Numinus Wellness (TSX: NUMI, OTCQB: NUMIF) has achieved a significant milestone as its Psychedelic-Assisted Therapy Training Program received official approval from Colorado state under the Natural Medicine Health Act (Proposition 122). This certification enables the company to train licensed professionals in providing psilocybin services.
The comprehensive certification pathway includes coursework in psychedelic-assisted therapy fundamentals, psilocybin-specific training, trauma-informed care, and practical applications. Healthcare practitioners, including therapists, social workers, and medical professionals, can enroll through an online application process, complete required courses, undergo supervised practicum in Colorado, and pass a final certification exam.
In a corporate update, Numinus disclosed that it has submitted all required information for its year-end financial audit and is working with auditors to complete the process and lift the current cease trade order.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced a transition in its Chief Financial Officer position. Kelvin Yang will take over as Interim CFO effective February 18, 2025, replacing Melony Valleau, who will conclude her interim tenure at the end of February. Yang brings regulatory and compliance experience and will oversee the company's financial operations as it pursues its strategic initiatives. The transition has been approved by the Board of Directors and aligns with ongoing corporate planning.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced a strategic wind-down of several non-operating subsidiaries through bankruptcy proceedings to streamline its corporate structure and improve operational efficiency. The affected subsidiaries include Mindspace Services Inc., Neurology Centre of Toronto Inc., Numinus Bioscience Inc., Salvation Bioscience Inc., and Numinus Health Corp.
The company emphasized that these actions will not affect Numinus Wellness Inc.'s ability to continue operations, as it maintains focus on its core research and training businesses in mental health solutions and psychedelic-assisted therapies. Dodick Landau Inc. has been engaged to oversee the bankruptcy proceedings, and the company will ensure completion of all required CRA filings for the affected entities.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced key leadership changes, with Michael Tan appointed as CEO, succeeding Payton Nyquvest who transitions to Executive Chair. Tan, who joined as COO in 2019 and became President in 2022, has overseen operations, M&A activities, and organizational realignments. In his new role, he will focus on strengthening clinical research and practitioner training programs while addressing emerging mental health care opportunities.
Nyquvest will remain actively involved in corporate strategy, investor relations, and strategic partnerships. The company also announced the resignation of Allen Morishita from its Board of Directors, who has served since Numinus' inception.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) provided an update on its previously announced management cease trade order (MCTO) regarding the filing of its audited annual financial statements, management discussion and analysis (MD&A), and annual information form (AIF) for the fiscal year ending August 31, 2024. The British Columbia Securities Commission granted the MCTO on December 2, 2024, under National Policy 12-203 (NP 12-203). This order restricts the company's CEO and CFO from trading in company securities until the filings are complete and the MCTO is revoked.
During this period, Numinus will halt share buy-back activities and refrain from issuing or acquiring securities from insiders or employees. Shareholders, however, can continue to trade their securities. The company anticipates finalizing the filings by January 28, 2025, and will issue a news release upon completion. Until then, Numinus will comply with NP 12-203 by issuing bi-weekly default status reports.
Since the last announcement, Numinus confirms it has met its obligations under NP 12-203, has not experienced any new defaults, is not undergoing insolvency proceedings, and has no undisclosed material information.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) provided an update regarding its management cease trade order (MCTO) related to delayed annual filings for the fiscal year ended August 31, 2024. The British Columbia Securities Commission granted the MCTO on December 2, 2024, restricting the CEO and CFO from trading company securities until the Annual Filings are completed.
During this period, the company has suspended its share buy-back program and prohibited securities transactions with insiders or employees. While shareholders can continue trading, the company expects to complete and file the Annual Filings by January 28, 2025. The delay is attributed to unexpected complications, and bi-weekly status updates will be provided on SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) has sold its five U.S. wellness clinics to Stella for US$3.53 million, marking a strategic shift towards an asset-light business model. The deal includes a data-sharing partnership to develop AI-based clinic management solutions for mental health providers.
The transaction terms include US$2.08 million paid at closing, US$750,000 in monthly installments throughout 2025, and potential earn-out compensation of up to US$0.7 million. Numinus will leverage its experience of serving 50,000 unique individuals and processing 250,000 insurance-reimbursed claims to develop solutions for an estimated market of 200,000 U.S. mental health care providers.
The company's Cedar Clinical Research has conducted 24 clinical trials with nearly 1,100 patients, while its practitioner training program has attracted almost 2,000 learners from 18 countries since May 2024.
FAQ
What is the current stock price of Numinus Wellness (NUMIF)?
What is the market cap of Numinus Wellness (NUMIF)?
